Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Organisation › Details

Petra Pharma Corporation

Petra is a pharmaceutical company dedicated to discovering and developing novel therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. PI pathways regulate fundamental processes of cellular growth and metabolism. PI-modifying enzymes are among the most frequently mutated proteins in cancer. Petra was founded in 2016 to advance the cutting-edge research of Dr. Lewis Cantley from Weill Cornell Medical Center and Dr. Nathanael Gray from Harvard Medical School and Dana-Farber Cancer Institute. Petra Pharma's office and lab headquarters is located at the Alexandria Center for Life Science, in New York. *

 

Period Start 2016-01-01 established
Products Industry PI3 kinase inhibitor
  Industry 2 Petra-01 (Petra Pharma Corp)
Person Person O’Callaghan, Brian (Petra Pharma 201804 CEO)
     
  Street 450 East 29th Street
  City 10016 New York, NY
  Tel +1-646-440-9210
    Address record changed: 2018-12-15
     
Basic data Employees n. a.
     
    * Document for �About Section�: Evotec AG. (4/11/18). "Press Release: Evotec Forms Collaboration with Petra Pharma on INDiGO Platform". Hamburg.
     
   
Record changed: 2018-12-15

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Petra Pharma Corporation


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px




» top